EFFICACY AND SAFETY OF FIXED-DOSE COMBINATION OF IRBESARTAN/ROSUVASTATIN IN PATIENTS WITH HYPERTENSION AND DYSLIPIDEMIA

被引：0
|
作者：
Kim, S. [1 ]
Lee, H. L. [2 ]
Kim, H. R. [1 ]
Seo, J. B. [1 ]
Chung, W. Y. [1 ]
Zo, J. H. [1 ]
Kim, M. A. [1 ]
机构：
[1] Seoul Natl Univ, Seoul Boramae Hosp, Coll Med, Seoul, South Korea
[2] Seoul Bukbu Hosp, Seoul, South Korea
来源：
JOURNAL OF HYPERTENSION | 2015年 / 33卷
关键词：
D O I：
10.1097/01.hjh.0000468363.20122.ca
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
PP.21.11
引用
收藏
页码：E321 / E322
页数：2
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF FIXED-DOSE COMBINATION OF ROSUVASTATIN AND IRBESARTAN IN PATIENTS WITH DYSLIPIDEMIA AND HYPERTENSION
    Kim, S. H.
    Lee, H. L.
    Kim, H. L.
    Seo, J. B.
    Chung, W. Y.
    Zo, J. H.
    Kim, M. A.
    Oh, B. H.
    ATHEROSCLEROSIS, 2014, 235 (02) : E264 - E264
  • [2] EFFICACY AND SAFETY OF FIXED-DOSE COMBINATION OF OLMESARTAN MEDOXOMIL AND ROSUVASTATIN IN KOREAN PATIENTS WITH HYPERTENSION AND DYSLIPIDEMIA
    Kim, S. H.
    Lee, H. L.
    Lim, W. H.
    Kim, H. L.
    Seo, J. B.
    Chung, W. Y.
    Zo, J. H.
    Kim, M. A.
    Kim, H. S.
    ATHEROSCLEROSIS, 2016, 252 : E57 - E57
  • [3] Efficacy and safety of fixed-dose combination of irbesartan/atorvastatin in patients with hypercholesterolemia and hypertension
    Kim, Sang-Hyun
    Lee, Hyang-Lim
    Kim, Hack-Lyoung
    Lim, Woo-Hyun
    Seo, Jae-Bin
    Chung, Woo-Young
    Zo, Joo-Hee
    Kim, Myung-A
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (16) : C155 - C155
  • [4] A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension
    Kim, Woohyeun
    Chang, Kiyuk
    Cho, Eun Joo
    Ahn, Jeong-Cheon
    Yu, Cheol Woong
    Cho, Kyoung-Im
    Kim, Yong-Jin
    Kang, Duk-Hyun
    Kim, Seok-Yeon
    Lee, Sang-Hak
    Kim, Ung
    Kim, Shin-Jae
    Ahn, Young Keun
    Lee, Chang Hoon
    Shin, Jin Ho
    Kim, Mikyung
    Park, Chang Gyu
    JOURNAL OF CLINICAL HYPERTENSION, 2020, 22 (02): : 261 - 269
  • [5] Irbesartan/HCTZ fixed-dose combination efficacy and safety in hypertensive obese patients from the inclusive trial
    Lewin, A.
    Weir, M.
    Cable, G.
    JOURNAL OF HYPERTENSION, 2007, 25 : S112 - S112
  • [6] The efficacy and safety of fixed-dose combinations of amlodipine and atorvastatin in the treatment of patients with concomitant hypertension and dyslipidemia
    Preston, RA
    Harvey, P
    Herfert, O
    Dykstra, G
    AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (05) : 185A - 185A
  • [7] Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized Trial
    Amedeo Vattimo, Antonio Carlos
    Helfestein Fonseca, Francisco Antonio
    Morais, Douglas Costa
    Generoso, Larissa Fontes
    Herrera, Renata
    Barbosa, Cristiane Moraes
    de Oliveira Izar, Maria Cristina
    Cardoso, Rita Antonelli
    Zung, Stevin
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2020, 93
  • [8] A fixed-dose lisinopril plus amlodipine plus rosuvastatin combination: prospects for its use in patients with hypertension and concomitant dyslipidemia
    Podzolkov, V. I.
    Bragina, A. E.
    Osadchiy, K. K.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (12) : 133 - 140
  • [9] Antihypertensive efficacy and safety of Irbesartan/HCTZ fixed-dose combination in obese patients with or without diabetes in the INCLUSIVE trial
    Lewin, Andrew J.
    Cable, Greg
    Weir, Matthew R.
    DIABETES, 2007, 56 : A694 - A694
  • [10] Strategic design and clinical evaluation of a fixed-dose combination tablet comprising valsartan, amlodipine, rosuvastatin and ezetimibe for patients with hypertension and dyslipidemia
    Kim, Tae-Kwang
    Lee, Jeong-Eun
    Jeong, Kyuho
    Baek, Min-Jun
    Kim, Dahan
    Jeon, Jun-Young
    Lee, Sangyoung
    Kim, Dae-Duk
    JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2024, 54 (01) : 99 - 112
12345